深创投 IDG资本 上海国投公司 红杉中国 同创伟业 君联资本 金浦投资 达晨财智 盛世投资 基石资本 中保投资 上海联和投资 CMC资本 中科创星 云锋基金 高榕创投 复星创富 元禾璞华 启明创投 东方富海 粤民投 ...

（上接1版） 同时，华福证券党委委员、副总裁蒋松荣代表公司与兴业银行、恒丰银行、基石资本、国泰基金、上海 证券报、道禾投资、上海钢联、杭州衡泰技术等8家单位签订战略合作协议。 作为华福证券重要战略伙伴，上海证券报后续将发挥开放、分享、共享的资本市场服务平台的功能，全 力助力华福证券作为福建省国资金融机构承担的社会责任，推动福建省经济社会高质量发展。在重大活 动、招商引资、咨询服务、城市名片推广等方面服务福建省政府，为更好服务国家战略作出积极贡献。 活动伊始，华福证券党委书记、董事长黄德良代表公司对福建省委、省政府，上级部门和监管单位及全 体股东单位和战略合作伙伴给予华福证券长期以来的关心指导和信任支持表示衷心感谢，并回顾了公司 近年来的经营发展与改革历程，同时对下一阶段实现特色化、差异化和高质量发展进行展望。 会上，薛鹤峰与黄德良共同为"华福证券股份有限公司"揭牌。 作为我国首批成立的证券公司之一，华福证券近年来的改革发展成效受到市场各方关注。去年12月，华 福证券增资扩股项目圆满落地，募资总额超过47.57亿元，超额完成预期目标，成为公司成立以来最大 一笔募资，同时募资规模也创下年度行业股权融资案例之最，充 ...

12月17日，华福证券股份有限公司成立大会暨战略合作签约仪式在福州举行。会上，"华福证券股份有 限公司"揭牌成立。同时，华福证券与兴业银行、恒丰银行、基石资本、国泰基金、上海证券报、道禾 投资、上海钢联、杭州衡泰技术等8家单位签订战略合作协议。目前，华福证券正在办理相关市场主体 登记及备案手续。 ...

证券之星消息，根据天眼查APP于12月10日公布的信息整理，北京宇石空间航天科技有限公司Pre-A轮 融资，融资额超亿人民币，参与投资的机构包括基石资本，兴湘集团，拓丰创投，银盈资本。 宇石空间成立于2024年，目前专注于大运力低成本快速复用液体火箭的研发和制造，是目前"国内唯一 采用不锈钢火箭+"筷子"捕获臂回收方案的团队"。公司致力于打破当前商业火箭价格高、产能低的发展 困境，为客户提供成本最低的快速复用液体火箭，其核心产品AS-1号火箭正处于二子级共底贮箱生产 阶段。 数据来源：天眼查APP 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-12-10 | 基石资本 兴湘集团 | 超亿人民币 | Pre-A轮 | | | 拓丰创投 | | | | | 银盈资本 | | | | 2025-05-28 | 千乘资本 华仓资本 | 亿级人民币 | 天使+ | | | 麟阁创投 | | | | | 云启资本 | | ...

Core Insights - The global biopharmaceutical industry is undergoing significant transformation, with breakthroughs in innovative drug development, synthetic biology, and gene therapy presenting unprecedented opportunities for human health [1] - Guangming District in Shenzhen is positioned as a key area for building a comprehensive national science center, focusing on innovative drug development and technology transfer, aiming to establish a new highland for the biopharmaceutical industry in the Greater Bay Area [1] Event Overview - The "Bay Area Pharmaceutical Research & Wisdom Gathering" seminar will be held on December 12, 2025, in Guangming, Shenzhen, focusing on innovative drug development, technology transfer pathways, and new opportunities for industry expansion [1] - The seminar will feature industry leaders such as Lizhu Biology and CITIC Construction Investment, providing insights into the transformation paths of innovative drug companies and the value reshaping trends in the industry chain for 2026 [1] Project Roadshow and Investment Opportunities - The seminar will include a project roadshow segment featuring three cutting-edge biopharmaceutical companies: Pamplona Biotech (Shenzhen), Hailike (Beijing), and Shenzhen Ruixing Biotechnology, showcasing their technological breakthroughs and commercial potential in targeted protein degradation and differentiated drug development [2] - A "Capital Face-to-Face" session will facilitate one-on-one discussions between financing companies and investors, with participation from renowned investment institutions such as Sequoia China, Gaotie Capital, and Cornerstone Capital, aimed at providing precise capital support and strategic guidance to biopharmaceutical companies [2] Collaborative Platform - The "Bay Area Pharmaceutical Research & Wisdom Gathering" serves as a high-end collaboration platform linking technology, capital, and industry, inviting experts, business leaders, and investment representatives to foster consensus and resource connections for high-quality development in the biopharmaceutical sector of the Greater Bay Area [2]

当前，全球生物医药产业正经历深刻变革，创新药研发、合成生物学、基因治疗等前沿技术加速突破， 为人类健康事业带来前所未有的机遇。光明区作为深圳建设综合性国家科学中心的核心承载区，在创新 药研发、科技成果转化等领域具备独特优势，正全力打造大湾区生物医药产业新高地。 为搭建行业交流合作平台，聚焦创新药研发前沿、科技成果转化路径及产业出海新机遇，由深圳市卫光 生命科技控股集团有限公司主办，深圳证券时报社有限公司作为媒体支持单位的"湾区药研 智汇光 明"粤港澳大湾区生物医药行业专题沙龙，将于2025年12月12日在深圳 光明银星合成生物产业园盛大举 行，共探生物医药高质量发展之道。 本次沙龙特别邀请了丽珠生物、中信建投（601066）等行业标杆嘉宾，深度解析创新药企业的蜕变路 径，展望2026年创新药产业链的价值重塑趋势，为参会者带来前沿的行业洞察与战略思考，助力企业明 晰发展方向、把握战略机遇。 为促进技术与资本的高效对接，沙龙特别设置优质项目路演环节。潘普洛纳生物科技（深圳）有限公 司、海徕科（北京）生物技术有限公司、深圳睿陉生物科技有限公司三家前沿生物医药企业，将集中展 示其在靶向蛋白降解、差异化多（双）抗药物开 ...

Core Viewpoint - The conference highlighted the necessity of building a sustainable and healthy innovation investment ecosystem in China, especially during the transition to high-quality economic development, with technology innovation as the core driver [1][4]. Group 1: Challenges in Early-Stage Investment - State-owned investment institutions face unique constraints in early-stage investments, including long cycles, high uncertainty, and unclear exit mechanisms, which require better alignment between GPs and LPs [1][2]. - The current reliance on government funding necessitates a more inclusive mechanism to encourage early-stage investments and diversify funding sources beyond just government capital [2][3]. - A stable legal framework is essential for addressing the challenges of early-stage investments, including long cycles and high uncertainty [2][3]. Group 2: Strategies for Successful Early-Stage Investment - Investment firms should focus on narrowing their investment scope to one or two core ecosystems to increase the success rate of early-stage investments [3]. - The emphasis should be on investing in people, as the success of early-stage investments relies heavily on the capabilities of the entrepreneurs and their understanding of market dynamics [4][5]. Group 3: Building an Efficient Innovation Ecosystem - There is a significant gap between passionate entrepreneurs and long-term value-seeking capital, highlighting the need for a more efficient and integrated innovation ecosystem [4][5]. - A successful dual-innovation ecosystem requires not only financial resources but also a conducive environment for the smooth flow of various resources, including technology and talent [5][6]. - High internal rates of return (IRR) are often found in projects that integrate trial production lines, scenario implementation, and industrial capital early in their development [6].

Group 1 - The launch of the technology innovation bonds on May 7 has received a positive market response, with active participation from technology companies and private equity institutions [1] - A total of 930 million yuan has been successfully issued and listed by four private equity institutions, supported by risk-sharing tools [1] - The application of risk-sharing tools is a core innovation in this bond issuance, addressing concerns of both issuers and investors, thereby filling a critical gap in the financing chain for technology innovation [1] Group 2 - The investor types for the recent technology innovation bonds include risk-sharing tools, banks, wealth management subsidiaries, and securities firms, indicating a diverse investor structure and high subscription multiples [2] - Nearly 300 companies have issued technology innovation bonds in the interbank market, including around 250 technology companies and nearly 50 private equity institutions [2] - The current technology innovation bonds have expanded scale and reduced costs compared to earlier pilot programs, effectively addressing challenges such as small scale, short duration, and difficulty in obtaining guarantees [2] Group 3 - The long-term structure design of "5+5" aligns with the duration requirements of many local government guidance funds in the venture capital field, enhancing the willingness of social limited partners (LPs) to participate [3] - The issuance of technology innovation bonds has introduced an intangible asset guarantee, replacing the previous requirement for physical asset guarantees, which reflects market recognition of quality fund managers' business models [3] - This new financing path is tailored to the characteristics of light asset operations in the venture capital industry, opening up new opportunities for funding [3]

Core Viewpoint - The issue of equity buybacks has become a focal point of controversy, with calls for friendly negotiation and long-term planning to lay the foundation for healthy corporate development and long-term returns for funds [1] Group 1: Industry Concerns - The China Securities Investment Fund Industry Association (CSIA) has issued an important reminder to private equity and venture capital fund managers, urging the industry to adopt long-term and value investment philosophies, set reasonable buyback terms, and resolve potential disputes amicably to maintain market stability and support the development of the real economy [1][3] - Since last year, the execution difficulties of equity buyback clauses have become a market focus, with some startup tech companies facing severe funding and development pressures due to triggering buyback clauses, while private equity and venture capital funds are caught in an "exit dilemma" affecting normal operations and investor returns [1][3] Group 2: Recommendations and Guidelines - CSIA emphasizes that private equity and venture capital fund managers should enhance their capabilities in value discovery, active management, and valuation pricing, and should ensure that buyback arrangements are scientifically reasonable and do not deviate from the essence of equity investment [3] - The core of CSIA's regulatory requirements for buyback clauses is to return to the essence of equity investment, which is "risk sharing and profit sharing," ensuring that both parties' rights and obligations are balanced [3][4] Group 3: Communication and Resolution - CSIA encourages fund managers to strengthen communication with investors and buyback obligors when buyback conditions are triggered, considering external factors such as macroeconomic conditions and industry policies [6] - The association advocates for a principle of "friendly negotiation and long-term planning" to explore diversified ways to resolve conflicts, such as adjusting buyback targets, extending buyback periods, and lowering buyback rates [6] Group 4: Practical Challenges - The application rate of buyback clauses in domestic primary market investment activities has exceeded 90%, leading to increased conflicts between startup companies and investment institutions [10] - Current challenges faced by investors exercising buyback rights include insufficient repayment capacity of buyback obligors, complex procedures for targeted capital reduction, and discrepancies in the legal nature of buyback rights [10][11] - The newly revised Company Law introduces a mechanism for minority shareholders to request the company to buy back their shares at a reasonable price when controlling shareholders seriously harm the interests of the company or other shareholders, enhancing protection for minority investors [10][11]

继6月18日5家民营股权投资机构获风险分担工具增信成功发行科创债后，除了盛景嘉成，基石资本、同 创伟业和道禾长期投资等3家机构，此次都进行了第二批民营创投科创债的发行路演，拟发行规模合计 9.3亿元。 经济观察网12月1日，北京盛景嘉成投资管理有限公司在中国银行间债券市场成功发行"北京盛景嘉成投 资管理有限公司2025年度第一期定向科技创新债券(分担工具)"，系第二批获得中国人民银行科技创新 债券风险分担工具支持的民营股权投资机构发行的科创债。 本期债券注册总规模4亿元，首期发行规模2亿元，首期发行期限"5+5"年。本项目创新引入风险分担工 具，由中债信用增进投资股份有限公司提供全额担保。 ...